key: cord-0991781-uageuenk
authors: Liu, Pengfei; Luo, Gang; Dodson, Matthew; Schmidlin, Cody J.; Wei, Yongyi; Kerimoglu, Baris; Ooi, Aikseng; Chapman, Eli; Garcia, Joe GN.; Zhang, Donna D.
title: The NRF2-LOC344887 signaling axis suppresses pulmonary fibrosis
date: 2020-10-20
journal: Redox Biol
DOI: 10.1016/j.redox.2020.101766
sha: 29ecc978cd12a150886018a060006f26783b6f8e
doc_id: 991781
cord_uid: uageuenk

Idiopathic pulmonary fibrosis (IPF) is a progressive and irreversible disease characterized by an increase in differentiation of fibroblasts to myofibroblasts and excessive accumulation of extracellular matrix in lung tissue. Pharmacological activation of NRF2 has proved to be a valuable antifibrotic approach, however the detailed mechanisms of how NRF2 mediates antifibrotic function remain unclear. In this study, we found that the antifibrotic function of sulforaphane (SFN), an NRF2 activator, was largely dependent on LOC344887, a long noncoding RNA. Two functional AREs were identified in both the promoter and intron 1 of LOC344887, which defines LOC344887 as a novel anti-fibrotic NRF2 target gene. RNA-seq analysis revealed that LOC344887 controls genes and signaling pathways associated with fibrogenesis. Deletion or downregulation of LOC344887 enhanced expression of CDH2/N-cadherin, as well as a number of other fibrotic genes and blunted the antifibrotic effects of SFN. Furthermore, LOC344887-mediated downregulation of fibrotic genes may involve the PI3K-AKT signaling pathway, as pharmacologic inhibition of PI3K activity blocked the effects of LOC344887 knockdown. Our findings demonstrate that NRF2-mediated LOC344887 upregulation contributes to the antifibrotic potential of SFN by repressing the expression of CDH2 and other fibrotic genes, providing novel insight into how NRF2 controls the regulatory networks of IPF. This study provides a better understanding of the molecular mechanisms of NRF2 activators against pulmonary fibrosis and presents a novel therapeutic axis for prevention and intervention of fibrosis-related diseases.

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease caused by different factors, such as environmental pollutants, drug side effects, and viral or fungal infection [1, 2, 3] . In fact, pulmonary fibrosis is also regarded as one of the major thoracic complications in patients with coronavirus disease 2019 (COVID-19) [4, 5] . Pulmonary fibrosis is characterized by activation of lung fibroblasts, excessive accumulation of extracellular matrix (ECM) in lung tissues, and progressive lung scarring. In recent years, the incidence of pulmonary fibrosis has increased sharply [2] , but effective treatments for fibrotic diseases are limited. The current treatments for pulmonary fibrosis, immunosuppressants (e.g. cyclophosphamide) and corticosteroids (e.g. dexamethasone), are limited in their potential because of severe side effects and low efficacy [6, 7] .

Nintedanib and pirfenidone, two drugs recently approved by the FDA for the treatment of pulmonary fibrosis, can slow down the progression of lung fibrosis and preserve lung function, however, neither of those drugs are able to reverse fibrosis. Furthermore, these new drugs display severe side effects, causing injury of many organs including the liver and skin [8, 9, 10, 11] .

Therefore, understanding the molecular events underlying the pathogenesis of IPF, coupled with developing novel and effective means of prevention/intervention that target early stages of fibrogenesis remain an important area of research.

Nuclear factor erythroid 2 (NFE2)-related factor 2 (NRF2) is an important transcription factor that regulates cellular antioxidant and anti-inflammatory responses by controlling expression of its target genes containing antioxidant response elements (AREs) in their regulatory regions. In response to oxidants and electrophiles, NRF2 forms heterodimeric complexes with small musculoaponeurotic fibrosarcoma (sMAF) protein and binds to AREs to transcriptionally activate its target genes and restore cellular homeostasis [12, 13, 14] . The role of NRF2 in pulmonary fibrosis has been investigated, and those studies indicate that NRF2 protects against the development of pulmonary fibrosis, indicating NRF2 activators could be used to inhibit fibrogenesis [15, 16, 17] . For instance, sulforaphane (SFN), a well-studied NRF2 activator, attenuates bleomycin-induced pulmonary fibrosis by effectively suppressing the epithelial-mesenchymal transition (EMT) process [15] , an effect that was also observed when NRF2 was activated by another inducer artemisitene [17] . In addition, trans-4,4'-dihydroxystilbene significantly ameliorates cigarette smoke-induced J o u r n a l P r e -p r o o f 4 pulmonary fibrosis via NRF2 activation [18] . Therefore, NRF2 activators hold promising potential to be developed into preventive agents against pulmonary fibrosis. The current mechanistic action of NRF2 activators against pulmonary fibrosis are thought to derive from its mediation of the antioxidant response and inhibition of EMT, which is essential for the overexpression of ECM genes [15, 19, 20] . However, the detailed molecular mechanisms linking NRF2 activation to the reduction of fibrogenesis are missing and warrant investigation.

Long noncoding RNAs (lncRNAs) have attracted widespread attention in various fields.

LncRNAs are non-coding transcripts longer than 200 nucleotides involved in various biological processes, such as cell proliferation and cell fate decisions. More importantly, aberrant IncRNA expression has been associated with developmental disorders and the pathogenesis of many human diseases [21, 22] . LncRNAs have also been demonstrated to play a role in pulmonary fibrosis. Knockdown of lncRNA H19 was able to attenuate pulmonary fibrosis in vitro and in vivo, through modulation of the miR-140-TGF-β/Smad3 signaling pathway [23] . LncRNA ZEB1-AS1 was reported to promote lung fibrosis by enhancing ZEB1-mediated EMT [24] . Another study demonstrated that lncRNA FENDRR also plays a role in mitigating pulmonary fibrosis [25] . Therefore, modulating lncRNAs has been considered as a novel therapeutic strategy for treating pulmonary fibrosis as well as other respiratory diseases. In this study, we report that a lncRNA, NmrA like redox sensor 2, pseudogene (NMRAL2P/LOC344887), is a novel anti-fibrotic NRF2 target gene that is largely responsible for the previously observed antifibrotic function of NRF2.

Knockdown or knockout of LOC344887 was associated with enhanced fibrosis, including increased expression of N-cadherin and ECM via the PI3K-AKT pathway.

J o u r n a l P r e -p r o o f 5

Sulforaphane (S6317), as well as anti-mouse IgG (HRP) (1:3000, A-9044) and anti-rabbit IgG (HRP) (1:3000, A-0545) antibodies were purchased from Sigma-Aldrich. LY294002 (ab120243) was purchased from Abcam. The rabbit normal IgG and antibodies against NRF2 (1:1000, sc-13032), sMAF (1:1000, sc-22831), NQO1 (1:1000, sc-32793), FN1 (1:1000, sc-8422), COL1A1

(1:1000, sc-293182), α-SMA (1:1000, sc-53142), N-Cadherin (1:500, sc-7939) and GAPDH (1:3000, sc-32233) were purchased from Santa Cruz Biotechnology. The antibody against E-Cadherin (1:1000, 610181) was purchased from BD Biosciences. Antibodies against AKT (1:2000, 4691S) and phospho-AKT (Ser473) (1:1000, 4060S) were purchased from Cell Signaling Technology. TGF-β (100-21) was purchased from PeproTech.

Human non-small cell lung cancer cell lines, NCI-H1299 and A549, human lung bronchus epithelial cell line, BEAS-2B, and human lung fibroblast cell line, HFL1, were purchased from American Type Culture Collection (ATCC). A549, H1299 and BEAS-2B cells were grown in DMEM medium supplemented with 10% FBS (Gibco, 26140-079) and 1% penicillin/streptomycin. HFL1 cells were cultured using DMEM:F12 Medium supplemented with 10% FBS and 1% penicillin/streptomycin. All cells were cultured in a humidified incubator at 37˚C with 5% CO 2 , and the medium was changed every two days.

LOC344887 knockout cells were generated using CRISPR-Cas9-mediated homologous recombination as reported previously [26, 27] . In brief, one single guide RNA (sgRNA) sequence was used to target the sequence around the insert point, and the sgRNA sequence is as follows:

5′-TCGTCCAGAGCTAGCTGATG-3′. The puromycin N-acetyltransferase (pac) plus a combined poly(A) and a transcriptional pause site (TPS), were inserted into the third intron (between +15770 and +15771, Figure 2A ). The positive cells were selected by puromycin treatment (3 μg/ml, Gibco), and the result was further confirmed by qPCR.

NRF2 knockout cells were generated using CRISPR-Cas9 mediated gene editing as per our J o u r n a l P r e -p r o o f 6 previous studies [28, 29] . A pair of sgRNA sequences (sgRNA-A:

5′-TATTTGACTTCAGTCAGCGA-3′; sgRNA-B: 5′-TAGTTGTAACTGAGCGAAAA-3′) were used to target coding sequences, and successful knockout was confirmed using immunoblot.

Total RNAs were extracted using TRIzol (Invitrogen) and further purified using RNeasy SAMtools, and the reading number of each gene was annotated with a custom in-house generated script.

Total mRNA was extracted using TRIzol (Invitrogen), and 2 μg of RNA was used to synthesize cDNA as reported previously [30, 31] . Herein, ACTB was used for all of qPCR normalization, and all experiments were performed in triplicate. The primer sequences (5′-3′) are as follows:

Both wild type and mutated 41-bp putative ARE-containing sequences ( Figure 1A ) were cloned into the pGL4.22-luciferase vector, and transfected using Lipofectamine 3000 (Invitrogen)

according to the manufacturer's instructions. In addition, luciferase activity was measured using the dual luciferase reporter assay system (Promega). For relative luciferase activity analysis, the value of Firefly-luciferase was normalized to the value of Renilla luciferase as reported previously [28, 29] .

Human LOC344887 siRNA (#5: SI04712344 and #8: SI05178838), human CDH2 siRNA (#5: SI02663927, #6: SI02757335, #10: SI04434612 and #11: SI04434619) and non-targeted control siRNA (SI03650318) were purchased from Qiagen. siRNA constructs were transfected using

Hiperfect reagent (Qiagen) as per the manufacturer's protocol. Briefly, 1×10 5 cells/well were seeded into a 12-well plate and transfected with different siRNAs (10 nM) for 72 h. Finally, the knockdown efficiency was evaluated via qPCR or immunoblot.

In our study, all of the cell samples were harvested using 1X Sample buffer (100 mM DTT, 2%

J o u r n a l P r e -p r o o f 8 SDS, 10% glycerol, 0.1% bromophenol blue and 50 mM Tris-HCl pH=8) and resolved by SDS-PAGE. The samples were further transferred onto a nitrocellulose membrane and blocked with 5% nonfat dried milk diluted in 1X PBS for 1h. The membrane was then incubated with primary antibody overnight at 4˚C, followed by incubation with secondary antibody for 1 h at room temperature. Finally, the protein bands were visualized using SuperSignal West Femto Maximum Sensitivity Substrate (Thermo Fisher Scientific) on the C600 Imaging System (Azure Biosystems).

The results in different groups were quantified using ImageJ 1.x (National Institutes of Health).

The CHIP-qPCR assay (EZ-CHIPTM, Merck, Germany) was performed as per our previous study [29] . For qPCR detection, 1 µL of purified DNA was amplified using primers specific for the sequence flanking the AREs located in the LOC344887 promoter and first intron. For qPCR, the following primers were used:

Biotin-DNA pull-down was performed as reported previously [28, 29] . Briefly, BEAS-2B cells were lysed using RIPA buffer containing 1 mM DTT (Golden Biotech), 1% protease inhibitor cocktail (Sigma-Aldrich) and 1 mM phenylmethylsulfonyl fluoride (PMSF, Thermo Fisher). Then the samples were precleared with streptavidin beads and further incubated with 2 μg of the biotinylated DNA probes overnight. The sequences of the different DNA probes are shown in Figure 1A . Finally, the DNA-protein complexes were pulled down using streptavidin beads and subjected to immunoblot analysis.

The results a presented as means ± SD. Statistical analysis was performed using SPSS 17.0.

Unpaired Student's t-tests were used to compare the means of two groups. One-way ANOVA with J o u r n a l P r e -p r o o f 9 Bonferroni's correction was used to analyze the means of three or more groups. P﹤0.05 was considered statistically significant.

To determine what lncRNAs might be regulated by NRF2 in lung cells, analysis of a Human

Transcriptome Array comparing all transcripts in BEAS-2B NRF2 +/+ vs. BEAS-2B NRF2 -/cell lines was performed. Interestingly, array analysis indicated a significant reduction in the expression of lncRNA (LOC344887) in NRF2 knockout cells compared to the wild type (data not shown). Figure 1C ). Furthermore, NRF2-sMAF binding to both ARE1 ( Figure 1D ) and ARE2 ( Figure 1E ) was confirmed using biotinylated 41-bp ARE-containing DNA probes, as ARE1-WT ( Figure 1D ) and ARE2-WT ( Figure 1E ) were only able to pull down NRF2 and sMAF in NRF2 +/+ cells, but not in NRF2 -/cells ( Figure 1D -E). Endogenous binding of NRF2 to ARE1 and ARE2 of LOC344887 was further confirmed using CHIP-qPCR ( Figure 1F ). In addition, the transcript level of LOC344887 was much lower in NRF2 -/cells, compared to NRF2 +/+ cells ( Figure   1G ), and was enhanced significantly by SFN in both H1299 and HFL1 wild type cell lines ( Figure   1H ). Importantly, the expression pattern of LOC344887 following loss of NRF2, or upon SFN treatment was similar to NQO1, a well-established NRF2 target gene ( Figure 1G-H) . Collectively, these results demonstrate that there are two functional AREs located in the promoter and intron 1 region of LOC344887, which defines LOC344887 as an NRF2 target gene in lung cells. , and FN1 (encoding fibronectin, a high-molecular weight extracellular matrix protein that binds to integrins), among others ( Figure 2F ).

To confirm the function of LOC344887 in controlling pulmonary fibrosis, LOC344887-siRNA was knockdown than Ctrl group, the induction of NQO1 by SFN was not affected by LOC344887 knockdown (Figure 3D -E).

Another gene whose expression is upregulated by the knockout of LOC344887 is CDH2, a gene that encodes the transmembrane cell adhesion protein N-Cadherin (N-Cad) ( Figure 4A ).

siRNA mediated knockdown of LOC344887 in HFL1 cells confirmed the transcriptional upregulation of CDH2, but not CDH1 ( Figure 4B ). The protein level of N-Cad was also enhanced when LOC344887 was knocked down ( Figure 4C-D) . Since N-Cad has been reported to be associated with EMT, a process known to contribute to lung fibrosis [32, 33] 

IPF is a progressive and irreversible lung disease with an average life expectancy of only 3 to 5 years after diagnosis in untreated patients [34, 35] . The current drugs used to treat pulmonary fibrosis slow down the progression of the disease and preserve lung function, but do not reverse or halt its progression. In addition, patients must balance the limited lung preserving effects and toxic side-effects associated with current drug regimes. Therefore, the development of better antifibrotic therapies, especially targeting early stages of pulmonary fibrosis, represents an unmet medical need. Targeting activation of the NRF2 pathway for IPF prevention or intervention has been investigated, and the therapeutic potential of NRF2 activators against pulmonary fibrosis has been demonstrated [15, 16, 17, 18, 20] . Also, the NRF2 activator SFN has recently been used in a phase II clinical trial to treat chronic obstructive pulmonary disease (NCT01335971).

Mechanistically, inhibition of EMT and TGF-β1/Smad signaling has been considered the major mechanism for the antifibrotic function of NRF2 [15, 18, 20] . In addition, treatment with SFN has been shown to suppress TGF-β1-induced EMT via decreased SNAIL protein levels, with SNAIL knockdown also abolishing the ability of SFN to reduce EMT and fibrosis [36] . These studies clearly indicate that NRF2 negatively regulates fibrogenic gene expression; however, which set of NRF2 targets is primarily responsible for reduced fibrogenesis is unclear. For example, it is unknown if the observed inhibition of EMT, compromised TGF-β1/Smad signaling, and decreased SNAIL expression in response to NRF2 activation is driven by antioxidant or anti-inflammatory NRF2 target genes. Interestingly, our study identified LOC344887 as an NRF2 target gene that was largely responsible for SFN-mediated antifibrotic activity in vitro. LOC344887 inhibited the expression of CDH2/N-cad via PI3K-AKT signaling pathway, which is essential for the progression of fibrosis, i.e. excess production of FN1, COL1A1, and ACTA2/α-SMA. This work provides a novel molecular insight into the antifibrotic function of NRF2 and highlights the importance of a specific NRF2 target gene, LOC344887, in suppressing pulmonary fibrosis.

LncRNAs have emerged as key regulators of many cellular processes, including chromatin remodeling, scaffolding, transcriptional and translational regulation, splicing modulation, and RNA degradation [37] . Proper function of lncRNAs has been demonstrated as a key mechanism J o u r n a l P r e -p r o o f 14 controlling cellular homeostasis and is critical in the development of organisms [37] . Dysregulation of lncRNAs has been associated with many human diseases [37] . In this study, we demonstrated that a lncRNA, LOC344887, is an anti-fibrotic NRF2 target gene with two functional AREs (Figure 1) that plays an important role in mediating fibrosis based on RNA-seq data analysis (Figure 2 ).

Functional analysis confirmed that LOC344887 negatively regulates fibrogenic gene expression ( Figure 3 and 4) . Importantly, the effects of SFN in reducing the expression of FN1, COL1A1, and ACTA2/α-SMA was largely abolished when LOC344887 was knocked down by siRNA (Figure 3 involves the modulation of antioxidant or anti-inflammatory pathways; however, the role of the NRF2-LOC344887 axis in mediating at least some aspects of the fibrotic stress response is clear.

Another important finding of this study is that LOC344887 regulates the expression of these fibrotic genes via inactivation of PI3K-AKT signaling ( Figure 5 ). It is reasonable to assume an indirect effect of LOC344887 on the PI3K-AKT pathways, considering the wide spectrum of roles that lncRNAs play in regulating cellular signaling networks. The detailed molecular events that link LOC344887 upregulation to dephosphorylation of AKT, thus blunting PI3K-AKT signaling, warrant further investigation.

The role of LOC344887 in cancer development has been investigated previously. The expression of LOC344887 is upregulated in hepatocellular carcinoma compared with normal tissue [38] . In other studies, LOC344887 might function as an oncogene in gallbladder cancer and colon cancer, as high expression of LOC344887 is associated with larger tumor size and the downregulation of LOC344887 inhibited cell proliferation in gallbladder cancer cells and colon cancer cells [39, 40] . These observations are in line with the "dark side" of NRF2 in cancer, i.e.

certain cancer cells have constitutively high NRF2 levels, which increases growth rate and leads to resistance to anti-cancer drug treatment. Clinically, high expression of NRF2 in patient tumors is strongly correlated with a poor prognosis. NRF2 is highly expressed in many cancer types including:

lung, head and neck, and bladder, due to somatic mutations in KEAP1 or NRF2 [41] . Furthermore, KEAP1 is mutated in lung cancer as frequently (>30%) as the tumor suppressor gene TP53 [12, 42, J o u r n a l P r e -p r o o f 15 43] . It would be interesting to dissect the degree of contribution of LOC344887 to the observed NRF2-dependent resistance and high proliferation in these cancer cells.

Recent recognition that a large fraction of the noncoding genome that was previously considered "junk" DNA actually encodes many lncRNAs, coupled with an increasing understanding of the diverse roles of IncRNAs in human disease, has created exciting new therapeutic opportunities [37] . Our study demonstrating that the antifibrotic activity of NRF2 is largely derived from this new NRF2 target gene LOC344887, provided an important new avenue for developing nucleic acid-based drugs to suppress fibrogenesis at early stages. However, studying LOC344887 in vivo has proved to be a challenge because LOC344887 is only found in the human genome, and a similar gene has not yet been identified in mice. If the mouse counterpart of the LOC344887 gene cannot be identified, a humanized mouse model might be desirable to study the in vivo function of LOC344887 in the future. At this point, we do not know if LOC344887 is expressed in a tissue-specific manner. If LOC344887 is also expressed in liver tissues, it would be interesting to investigate if LOC344887 also negatively regulates liver fibrosis. In addition, our study also indicates an effect of LOC344887 on the PI3K-AKT signaling pathway. Therefore, other diseases related with PI3K-AKT signaling, such as ischemia/reperfusion injury [44] and diabetes [45] , could also be affected by LOC344887, along with cancer and fibrosis. COL13A1  COL1A1  COL4A1  COL4A2  COL4A3  COL4A4  COL4A5  COL4A6  COL5A1  COL6A2  COL6A3  DCN  FGF2  FGG  FN1  ITGA1  ITGA11  ITGA2  ITGA5  ITGAV  ITGB3  ITGB4  ITGB6  LAMA4  LAMB3  LAMC2  LUM  NID1  NPNT  PDGFB  SERPINE1  SPARC  TGFBI  THBS1 COL1A1  FN1  NRF2  NQO1  I  II  III IV  I  II  III 

Cleavage factor 25 deregulation contributes to pulmonary fibrosis through alternative polyadenylation

Trends in mortality from idiopathic pulmonary fibrosis in the European Union: an observational study of the WHO mortality database from 2001-2013

COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection

Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy

Corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis: a single center experience and literature review

Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis

Parthenolide attenuated bleomycin-induced pulmonary fibrosis via the NF-kappaB/Snail signaling pathway

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial

Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis: A single-center experience

NRF2 and the Hallmarks of Cancer

Redox regulation by NRF2 in aging and disease

Molecular basis of the Keap1-Nrf2 system

Nrf2 antioxidant pathway suppresses Numb-mediated epithelial-mesenchymal transition during pulmonary fibrosis

Oxidative stress and antioxidants in the pathogenesis of pulmonary fibrosis: a potential role for Nrf2

Artemisitene activates the Nrf2-dependent antioxidant response and protects against bleomycin-induced lung injury

Trans-4,4'-dihydroxystilbene ameliorates cigarette smoke-induced progression of chronic obstructive pulmonary disease via inhibiting oxidative stress and inflammatory response

Downregulation of HMGB1 is required for the protective role of Nrf2 in EMT-mediated PF

Polydatin attenuates reactive oxygen species-induced airway remodeling by promoting Nrf2-mediated antioxidant signaling in asthma mouse model

Mechanisms of long noncoding RNA function in development and disease

Functional Classification and Experimental Dissection of Long Noncoding RNAs

Knockdown of Long Noncoding RNA H19 Represses the Progress of Pulmonary Fibrosis through the Transforming Growth Factor

beta/Smad3 Pathway by Regulating MicroRNA 140

lncRNA ZEB1-AS1 promotes pulmonary fibrosis through ZEB1-mediated epithelial-mesenchymal transition by competitively binding miR-141-3p

Long Noncoding RNA FENDRR Exhibits Antifibrotic Activity in Pulmonary Fibrosis

Genome engineering using the CRISPR-Cas9 system

Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity

NRF2 negatively regulates primary ciliogenesis and hedgehog signaling

RPA1 binding to NRF2 switches ARE-dependent transcriptional activation to ARE-NRE-dependent repression

Activation Confers Greater Cellular Protection than Covalent Activation

p97 Negatively Regulates NRF2 by Extracting Ubiquitylated NRF2 from the KEAP1-CUL3 E3 Complex

N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties

Replacement of E-cadherin by N-cadherin in the mammary gland leads to fibrocystic changes and tumor formation

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

Nrf2 inhibits epithelial-mesenchymal transition by suppressing snail expression during pulmonary fibrosis

Long noncoding RNAs: cellular address codes in development and disease

Identifying hub genes and dysregulated pathways in hepatocellular carcinoma

The NmrA-like family domain containing 1 pseudogene Loc344887 is amplified in gallbladder cancer and promotes epithelial-mesenchymal transition

A functional pseudogene, NMRAL2P, is regulated by Nrf2 and serves as a coactivator of NQO1 in sulforaphane-treated colon cancer cells

Discovery and saturation analysis of cancer genes across 21 tumour types

Dual roles of Nrf2 in cancer

Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers

Inhibition of Brd4 alleviates renal ischemia/reperfusion injury-induced apoptosis and endoplasmic reticulum stress by blocking FoxO4-mediated oxidative stress

Long Noncoding RNA lncSHGL Recruits hnRNPA1 to Suppress Hepatic Gluconeogenesis and Lipogenesis

Extracellular matrix organization [GO:0030198] Homophilic cell adhesion [GO:0007156] Positive regulation of cell migration

Cell-substrate junction assembly

This work was supported by the following NIH grants: R35 ES031575, P42 ES004940, and R01 DK109555 to DDZ, R01 ES031463 to EC and R01 HL91889, P01 HL126609, R01 HL125615, and P01 HL134610 to JGNG.. J o u r n a l P r e -p r o o f

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.